BR112023019370A2 - Composto, e, composição farmacêutica para prevenir, melhorar ou tratar câncer - Google Patents
Composto, e, composição farmacêutica para prevenir, melhorar ou tratar câncerInfo
- Publication number
- BR112023019370A2 BR112023019370A2 BR112023019370A BR112023019370A BR112023019370A2 BR 112023019370 A2 BR112023019370 A2 BR 112023019370A2 BR 112023019370 A BR112023019370 A BR 112023019370A BR 112023019370 A BR112023019370 A BR 112023019370A BR 112023019370 A2 BR112023019370 A2 BR 112023019370A2
- Authority
- BR
- Brazil
- Prior art keywords
- egfr
- compound
- pharmaceutical composition
- cancer
- present
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 230000037430 deletion Effects 0.000 abstract 2
- 238000012217 deletion Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
composto, e, composição farmacêutica para prevenir, melhorar ou tratar câncer. a presente invenção refere-se a uma composição farmacêutica para prevenção e tratamento de uma doença de câncer, incluindo câncer de pulmão causado por crescimento celular anormal, contendo um novo derivado de pirimidina trissubstituída com atividade inibidora contra proteínas quinases, incluindo egfr, e um sal farmaceuticamente aceitável do mesmo, como ingredientes ativos. o novo composto da presente invenção tem uma excelente atividade inibidora contra proteínas quinases. particularmente, o novo composto da presente invenção apresenta efeitos inibidores potentes contra vários mutantes de egfr resistentes aos fármacos (incluindo deleção de éxon 19-t790m-c797s-egfr, l858r-t790m-c797s-egfr, deleção de éxon 19-t790m-egfr, e l858r-t790m-egfr) e é utilizável como um agente profilático e terapêutico para doenças de câncer causadas por estes mutantes de egfr.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210042821 | 2021-04-01 | ||
| KR1020220039968A KR20220136931A (ko) | 2021-04-01 | 2022-03-30 | 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| PCT/KR2022/004702 WO2022211573A1 (ko) | 2021-04-01 | 2022-04-01 | 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019370A2 true BR112023019370A2 (pt) | 2023-12-26 |
Family
ID=83456614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019370A BR112023019370A2 (pt) | 2021-04-01 | 2022-04-01 | Composto, e, composição farmacêutica para prevenir, melhorar ou tratar câncer |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4286376A1 (pt) |
| JP (1) | JP2024511514A (pt) |
| AU (1) | AU2022250976A1 (pt) |
| BR (1) | BR112023019370A2 (pt) |
| CA (1) | CA3207015A1 (pt) |
| IL (1) | IL307327A (pt) |
| MX (1) | MX2023010016A (pt) |
| WO (1) | WO2022211573A1 (pt) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120172384A1 (en) * | 2009-06-18 | 2012-07-05 | Mihiro Sunose | Heterocyclylaminopyrimidines as kinase inhibitors |
| JOP20190281A1 (ar) * | 2017-06-13 | 2019-12-02 | Korea Res Inst Chemical Tech | مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه |
| CN110944989B (zh) | 2017-07-19 | 2021-06-25 | 正大天晴药业集团股份有限公司 | 作为egfr激酶抑制剂的芳基磷氧化合物 |
| WO2019112344A1 (ko) | 2017-12-07 | 2019-06-13 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
| CN110305161A (zh) * | 2018-03-20 | 2019-10-08 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| KR20190114910A (ko) | 2018-03-30 | 2019-10-10 | 한미약품 주식회사 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 |
| WO2020147702A1 (en) | 2019-01-17 | 2020-07-23 | Betta Pharmaceuticals Co., Ltd | Egfr inhibitors, compositions and methods thereof |
| WO2020216371A1 (zh) * | 2019-04-26 | 2020-10-29 | 江苏先声药业有限公司 | Egfr抑制剂及其应用 |
| CN112538072B (zh) * | 2019-09-21 | 2024-02-06 | 齐鲁制药有限公司 | 氨基嘧啶类egfr抑制剂 |
-
2022
- 2022-04-01 BR BR112023019370A patent/BR112023019370A2/pt unknown
- 2022-04-01 MX MX2023010016A patent/MX2023010016A/es unknown
- 2022-04-01 IL IL307327A patent/IL307327A/en unknown
- 2022-04-01 AU AU2022250976A patent/AU2022250976A1/en active Pending
- 2022-04-01 CA CA3207015A patent/CA3207015A1/en active Pending
- 2022-04-01 EP EP22781692.3A patent/EP4286376A1/en active Pending
- 2022-04-01 JP JP2023559714A patent/JP2024511514A/ja active Pending
- 2022-04-01 WO PCT/KR2022/004702 patent/WO2022211573A1/ko active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| IL307327A (en) | 2023-11-01 |
| EP4286376A1 (en) | 2023-12-06 |
| MX2023010016A (es) | 2023-09-07 |
| CA3207015A1 (en) | 2022-10-06 |
| WO2022211573A1 (ko) | 2022-10-06 |
| AU2022250976A1 (en) | 2023-08-17 |
| JP2024511514A (ja) | 2024-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023015527A2 (pt) | Inibidores de cdk e métodos de uso destes | |
| BR112023015067A2 (pt) | Composto de quinazolina para induzir a degradação de proteína kras g12d mutante | |
| TN2020000160A1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| JP2008513407A (ja) | 中枢神経由来の神経障害性疼痛の治療用テトロドトキシンおよびその誘導体 | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| NZ766141A (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis | |
| BR112023019370A2 (pt) | Composto, e, composição farmacêutica para prevenir, melhorar ou tratar câncer | |
| BR112023025841A2 (pt) | Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma | |
| MX2023004537A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| BR112022015046A2 (pt) | Uso de forsitina e/ou seus derivados, método para a inibição da proteína 3clpro do vírus covid-19, uso de composição de forsitina/forsitosídeo, métodos para uso contra o vírus covid-19 ou para o tratamento de doenças causadas pelo vírus covid-19, composição de forsitina/forsitosídeo e medicamento compreendendo uma composição de forsitina/forsitosídeo | |
| Nunta-Aree et al. | SW2-year outcomes of subthalamic deep brain stimulation for idiopathic Parkinson’s disease | |
| WO2018226058A3 (ko) | 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 | |
| BR112022016743A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112021017829A2 (pt) | Composto, e, composição farmacêutica para uso em prevenir ou tratar câncer | |
| BR112021026754A2 (pt) | Composto, métodos para tratar um paciente com uma doença ou transtorno suscetível, para inibir janus quinase e para tratar uma ou mais doenças ou transtornos de inflamação, disfunção autoimune e câncer, composição, combinação, e, uso de um composto | |
| WO2023220131A3 (en) | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | |
| Parveen et al. | Molecular docking study of catecholamines and [4-(propan-2-yl) phenyl] carbamic acid with tyrosine hydroxylase | |
| MX2023007150A (es) | Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos. | |
| CN117769419A (zh) | 用于在皮肤神经纤维瘤的治疗中使用的硝羟喹啉 | |
| AU2020299145A8 (en) | Compositions and methods for treating eye diseases | |
| BR112022008571A2 (pt) | Composto de azabenzimidazol e medicamento | |
| MX2021016055A (es) | Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis. | |
| MX2022009485A (es) | Composiciones para el tratamiento de enfermedades. | |
| BR112020025302A2 (pt) | Aumento de ações antibacterianas de um antibiótico depsipeptídico usando quantidades sinérgicas de ácido bórico | |
| BR112021016996A8 (pt) | Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana |